WSJ: Pfizer looks at restructuring R&D, new cuts

The Wall Street Journal reports that Pfizer's new CEO, Jeffrey Kindler (photo), is preparing to announce new job cuts on Monday, as he steps up the company's restructuring efforts. As part of the new approach, Kindler is evidently looking at containing R&D expenses while making cuts in marketing and administration. At the same time, company insiders tell the JoIurnal that Kindler is considering reorganizing scientists into disease groups, in order to hold the company's scientists accountable for their results.

- here's the article from The Wall Street Journal (sub. req.)

Related Articles:
What's next for Pfizer? Report
Pfizer to axe 2,200 sales jobs in realignment. Report
Pfizer's Kindler leaves analysts feeling flat. Report
CEO McKinnell gets the boot as Pfizer struggles. Report

Suggested Articles

The patient was hospitalized with febrile neutropenia in the weeks after receiving the drug and died 52 days post-treatment with the CAR-T therapy.

The trial has been paused since early September while FDA reviews the safety of the vaccine in light of a reported case of an inflammatory disorder.

Biogen is cutting its experimental multiple sclerosis drug opicinumab as well as an spinal muscular atrophy candidate amid a third-quarter clear-out.